Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rommer

Showing results (151-160 of 220) with videos related to

Pageof 22
Sort By:
Acta Neuropathologica Communications|August 10, 2016
Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SDBleranda Zeka, Maria Hastermann, Nathalie Kaufmann, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 27, 2021
Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis RegistryStefan J Blaschke, David Ellenberger, Peter Flachenecker, et al.
Frontiers in Aging Neuroscience|September 8, 2022
Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer's diseaseTandis Parvizi, Theresa König, Raphael Wurm, et al.
European Journal of Neurology|November 27, 2024
Autoimmune screening panel in patients with multiple sclerosis: A Vienna multiple sclerosis database studyFabian Föttinger, Nik Krajnc, Katharina Riedl, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|January 16, 2026
Association of treatment decision with personality, coping strategies and impulsivity in patients with multiple sclerosisJan Philipp Nolte, Fabian Föttinger, Nik Krajnc, et al.
Plos One|July 27, 2021
COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registryGabriel Bsteh, Hamid Assar, Harald Hegen, et al.
Journal of Neurology|November 19, 2025
Safety of disease-modifying therapies in multiple sclerosis: real-world data from the Austrian MS Treatment Registry (AMSTR)Tobias Monschein, Helena Untersteiner, Markus Ponleitner, et al.
Neuroimage. Clinical|October 15, 2023
Metabolic Insights into Iron Deposition in Relapsing-Remitting Multiple Sclerosis via 7 T Magnetic Resonance Spectroscopic ImagingAlexandra Lipka, Wolfgang Bogner, Assunta Dal-Bianco, et al.
Journal of Neuroinflammation|March 19, 2020
Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndromePatrick Altmann, Desiree De Simoni, Alexandra Kaider, et al.
Journal of Neurology|April 19, 2023
Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)Tobias Monschein, Sarinah Dekany, Tobias Zrzavy, et al.
Pageof 22

Showing results (151-160 of 220) with videos related to

Sort By:
Pageof 22
Acta Neuropathologica Communications|August 10, 2016
Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SDBleranda Zeka, Maria Hastermann, Nathalie Kaufmann, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 27, 2021
Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis RegistryStefan J Blaschke, David Ellenberger, Peter Flachenecker, et al.
Frontiers in Aging Neuroscience|September 8, 2022
Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer's diseaseTandis Parvizi, Theresa König, Raphael Wurm, et al.
European Journal of Neurology|November 27, 2024
Autoimmune screening panel in patients with multiple sclerosis: A Vienna multiple sclerosis database studyFabian Föttinger, Nik Krajnc, Katharina Riedl, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|January 16, 2026
Association of treatment decision with personality, coping strategies and impulsivity in patients with multiple sclerosisJan Philipp Nolte, Fabian Föttinger, Nik Krajnc, et al.
Plos One|July 27, 2021
COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registryGabriel Bsteh, Hamid Assar, Harald Hegen, et al.
Journal of Neurology|November 19, 2025
Safety of disease-modifying therapies in multiple sclerosis: real-world data from the Austrian MS Treatment Registry (AMSTR)Tobias Monschein, Helena Untersteiner, Markus Ponleitner, et al.
Neuroimage. Clinical|October 15, 2023
Metabolic Insights into Iron Deposition in Relapsing-Remitting Multiple Sclerosis via 7 T Magnetic Resonance Spectroscopic ImagingAlexandra Lipka, Wolfgang Bogner, Assunta Dal-Bianco, et al.
Journal of Neuroinflammation|March 19, 2020
Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndromePatrick Altmann, Desiree De Simoni, Alexandra Kaider, et al.
Journal of Neurology|April 19, 2023
Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)Tobias Monschein, Sarinah Dekany, Tobias Zrzavy, et al.
Pageof 22